110 related articles for article (PubMed ID: 23624215)
1. Immunomodulatory effects of silymarin in patients with β-thalassemia major.
Gharagozloo M; Karimi M; Amirghofran Z
Int Immunopharmacol; 2013 Jun; 16(2):243-7. PubMed ID: 23624215
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
[TBL] [Abstract][Full Text] [Related]
3. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients.
Alidoost F; Gharagozloo M; Bagherpour B; Jafarian A; Sajjadi SE; Hourfar H; Moayedi B
Int Immunopharmacol; 2006 Aug; 6(8):1305-10. PubMed ID: 16782543
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of TGFβ, IL-10, IL-17, and IL-23 cytokines in β-thalassemia major patients: the impact of silymarin therapy.
Balouchi S; Gharagozloo M; Esmaeil N; Mirmoghtadaei M; Moayedi B
Immunopharmacol Immunotoxicol; 2014 Aug; 36(4):271-4. PubMed ID: 24945737
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
7. Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity.
Gharagozloo M; Karimi M; Amirghofran Z
Ann Hematol; 2009 Jan; 88(1):21-7. PubMed ID: 18690440
[TBL] [Abstract][Full Text] [Related]
8. The influence of iron loading and iron chelation on the proliferation and telomerase activity of human peripheral blood mononuclear cells.
Bagherpour B; Gharagozloo M; Moayedi B
Iran J Immunol; 2009 Mar; 6(1):33-9. PubMed ID: 19293476
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
Zareifar S; Jabbari A; Cohan N; Haghpanah S
Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772
[TBL] [Abstract][Full Text] [Related]
10. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
[TBL] [Abstract][Full Text] [Related]
11. Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases.
Gharagozloo M; Javid EN; Rezaei A; Mousavizadeh K
Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):251-6. PubMed ID: 23121838
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
[TBL] [Abstract][Full Text] [Related]
14. The impact of silymarin on antioxidant and oxidative status in patients with β-thalassemia major: A crossover, randomized controlled trial.
Darvishi-Khezri H; Salehifar E; Kosaryan M; Karami H; Alipour A; Shaki F; Aliasgharian A
Complement Ther Med; 2017 Dec; 35():25-32. PubMed ID: 29154063
[TBL] [Abstract][Full Text] [Related]
15. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
16. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
[TBL] [Abstract][Full Text] [Related]
17. Intravenous chelation therapy during transplantation for thalassemia.
Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
[TBL] [Abstract][Full Text] [Related]
18. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of silymarin with iron chelators in transfusion-dependent β-thalassemia patients: a systematic review and meta-analysis for effect on iron overload.
Darvishi-Khezri H; Naderisorki M; Zahedi M; Mortazavi P; Tajik F; Nasirzadeh A; Karami H
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1445-1453. PubMed ID: 34486906
[No Abstract] [Full Text] [Related]
20. Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat.
Najafzadeh H; Jalali MR; Morovvati H; Taravati F
J Med Toxicol; 2010 Mar; 6(1):22-6. PubMed ID: 20182837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
